FIG 1.
Patient disposition. EFS, event-free survival; IDFS, invasive disease-free survival; TCH+P, docetaxel, carboplatin, and trastuzumab plus pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.